Skip to main content

Table 2 Clinical manifestation

From: Study on clinical and biological characteristics of ameloblastic carcinoma

Patient no

Location

Sex/year

S/C/R (times)

Course (year)

Follow-up time (month)

R-t/Treatment

BRAF-V600E

Type

1

Maxilla

F/53

2/0/0

1

32

1/Conservative

+

Primary

2

Mandible

M/64

1/3/0

0.5

26

0/Radical + ND + C

+

 

3

Mandible

F/63

1/0/0

20

82

0/Radical + ND + RC

NP

 

4

Mandible

M/52

2/0/0

0.5

21

1/Conservative

+

 

5

Mandible

F/66

2/0/0

18

40

1/Radical + RC

NP

Secondary

6

Mandible

F/60

2/0/0

4.5

36

1/Conservative

NP

 

7

Mandible

M/43

1/2/0

18

14

0/Radical + C

NP

 

8

Mandible

F/28

4/0/0

8

21

2/Conservative; 1/Radical

NP

 

9

Mandible

M/61

4/0/0

2.3

69

1/Radical + RC;1/Conservative; 1/Radical

+

 

10

Mandible

F/75

3/0/0

5

78

1/Conservative; 1/Radical

NP

 

11

Mandible

M/25

2/0/1

1.5

69

1/Radical + RC;1/Conservative

+

 

12

Mandible

M/24

3/0/0

6

52

1/Conservative;1/Radical

NP

 

13

Maxilla

F/68

8/0/1

41

54

6/Conservative;1/Radical

NP

 

14

Mandible

M/51

1/0/0

13

67

0/Radical + RC

NP

 

15

Mandible

M/36

4/1/0

15

5

3/Conservative

NP

 
  1. F Female; M Male; S Surgery; C Chemotherapy; R Radiotherapy; R-t Recurrence-times; RC Reconstruction; ND Neck dissection; NP Not performed